Immunotherapy for Colorectal Cancer
The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic populat...
Main Authors: | Patrick M. Boland, Wen Wee Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/9/5/50 |
Similar Items
-
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
by: Yuyin Fu, et al.
Published: (2021-07-01) -
Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
by: Forero Ivan, et al.
Published: (2012-05-01) -
Some aspects of immunotherapy in colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2018-05-01) -
Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
by: Jack M. Qian, et al.
Published: (2021-02-01) -
Immunotherapy for Gastroesophageal Cancer
by: Emily F. Goode, et al.
Published: (2016-09-01)